Combined microwave ablation and antiangiogenic therapy to increase local efficacy

References

• Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14:199–208.
   PubMed Web of Science ®Google Scholar
• De BT, Tselikas L, Gravel G, et al. Lung ablation: Best practice/results/response assessment/role alongside other ablative therapies. Clinical Radiol. 2017;72:657–664.
   PubMed Web of Science ®Google Scholar
• Yang X, Ye X, Huang G, et al. Repeated percutaneous microwave ablation for local recurrence of inoperable Stage I nonsmall cell lung cancer. J Can Res Ther. 2017;13:683–688.
   PubMed Web of Science ®Google Scholar
• Ni Y, Bi J, Ye X, et al. Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study. Medicine (Baltimore). 2016;95:e3998
   PubMed Web of Science ®Google Scholar
• Yang X, Ye X, Lin Z, et al. Computed tomography-guided percutaneous microwave ablation for treatment of peripheral ground-glass opacity-Lung adenocarcinoma: A pilot study. J Can Res Ther. 2018;14:764–771.
   PubMed Web of Science ®Google Scholar
• North DA, Groeschl RT, Sindram D, et al. Microwave ablation for hepatic malignancies: a call for standard reporting and outcomes. Am J Surg. 2014;208:284–294.
   PubMed Web of Science ®Google Scholar
• Ye X, Fan W, Wang H, et al. Expert consensus workshop report: guidelines for thermal ablation of primary and metastatic lung tumors (2018 edition). J Can Res Ther. 2018;14:730–744.
   PubMed Web of Science ®Google Scholar
• Chen ZW, Lin ZY, Chen YP, et al. Clinical efficacy of endovascular radiofrequency ablation in the treatment of portal vein tumor thrombus of primary hepatocellular carcinoma. J Can Res Ther. 2018;14:145–149.
   PubMed Web of Science ®Google Scholar
• Ierardi AM, Floridi C, Fontana F, et al. Microwave ablation of liver metastases to overcome the limitations of radiofrequency ablation. Radiol Med. 2013;118:949–961.
   PubMed Web of Science ®Google Scholar
• Fan W, Li X, Zhang L, et al. Comparison of microwave ablation and multipolar radiofrequency ablation in vivo using two internally cooled probes. AJR Am J Roentgenol. 2012;198:W46–W50.
   PubMed Web of Science ®Google Scholar
• Chen J, Lin ZY, Wu ZB, et al. Magnetic resonance imaging evaluation after radiofrequency ablation for malignant lung tumors. J Can Res Ther. 2017;13:669–675.
   PubMed Web of Science ®Google Scholar
• Hertzanu Y, Ye X. Computed tomography-guided percutaneous microwave ablation: A new weapon to treat ground-glass opacity–lung adenocarcinoma. J Can Res Ther. 2019;15:265–266.
   PubMed Web of Science ®Google Scholar
• Wei Z, Ye X, Yang X, et al. Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone. Med Oncol. 2015;32:464.
   PubMed Web of Science ®Google Scholar
• Vogl TJ, Qian J, Tran A, et al. Study on the effect of chemoembolization combined with microwave ablation for the treatment of hepatocellular carcinoma in rats. Diagn Interv Radiol. 2017;23:150–155.
   PubMed Web of Science ®Google Scholar
• Song Z, Qi H, Zhang H, et al. Microwave ablation: Results with three different diameters of antennas in ex vivo bovine and in vivo porcine liver. J Can Res Ther. 2017;13:737–741.
   PubMed Web of Science ®Google Scholar
• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15–18.
   PubMed Web of Science ®Google Scholar
• O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277–285.
   PubMed Web of Science ®Google Scholar
• Ni Y, Ye X, Wan C, et al. Percutaneous microwave ablation (MWA) increased the serum levels of VEGF and MMP-9 in Stage I non-small cell lung cancer (NSCLC). Int J Hyperthermia. 2017;33:1–5.
   PubMed Web of Science ®Google Scholar
• Jones-Bolin S. Guidelines for the care and use of laboratory animals in biomedical research. Curr Protoc Pharmacol. 2012;59:A.4B.1–A.4B.9.
   Google Scholar
• Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727–739.
   PubMed Web of Science ®Google Scholar
• Hu TH, Huang CC, Wu CL, et al. Increased endostatin/collagen XVIII expression correlates with elevated VEGF level and poor prognosis in hepatocellular carcinoma. Mod Pathol. 2005;18:663–672.
   PubMed Web of Science ®Google Scholar
• Cheng D, Liang B, Li Y. Clinical value of vascular endothelial growth factor and endostatin in urine for diagnosis of bladder cancer. Tumori. 2012;98:762–767.
   PubMed Web of Science ®Google Scholar
• Landt S, Mordelt K, Schwidde I, et al. Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer. Anticancer Res. 2011;31:2651–2655.
   PubMed Web of Science ®Google Scholar
• Kantola T, Vayrynen JP, Klintrup K, et al. Serum endostatin levels are elevated in colorectal cancer and correlate with invasion and systemic inflammatory markers. Br J Cancer. 2014;111:1605–1613.
   PubMed Web of Science ®Google Scholar
• Chen Z, Guo W, Cao J, et al. Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial. Cancer Chemother Pharmacol. 2015;75:547–557.
   PubMed Web of Science ®Google Scholar
• Chen J, Yao Q, Li D, et al. Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study. BMC Cancer. 2013;13:248.
   PubMed Web of Science ®Google Scholar
• Zhao P, Luo R, Wu J, et al. E10A, an adenovirus carrying human endostatin gene, in combination with docetaxel treatment inhibits prostate cancer growth and metastases. J Cell Mol Med. 2010;14:381–391.
   PubMed Web of Science ®Google Scholar
• Ke QH, Zhou SQ, Huang M, et al. Early efficacy of Endostar combined with chemoradiotherapy for advanced cervical cancers. Asian Pac J Cancer Prev. 2012;13:923–926.
   PubMedGoogle Scholar
• Mo HY, Luo DH, Qiu HZ, et al. Elevated serum endostatin levels are associated with poor survival in patients with advanced-stage nasopharyngeal carcinoma. Clin Oncol (R Coll Radiol). 2013;25:308–317.
   PubMed Web of Science ®Google Scholar
• Kong J, Pan B, Ke S, et al. Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1alpha/VEGFA. PLoS One. 2012;7:e37266.
   PubMed Web of Science ®Google Scholar
• Xu M, Xie XH, Xie XY, et al. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo. Acta Radiol. 2013;54:199–204.
   PubMed Web of Science ®Google Scholar
• Jun HY, Ryu JH, Byun SJ, et al. Combined radiofrequency ablation and double anti-angiogenic protein therapy to increase coagulation efficacy: an experimental study in a murine renal carcinoma model. Korean J Radiol. 2015;16:776–782.
   PubMed Web of Science ®Google Scholar
• Kim YM, Hwang S, Pyun BJ, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem. 2002;277:27872–27879.
   PubMed Web of Science ®Google Scholar
• Kim YM, Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 2000;60:5410–5413.
   PubMed Web of Science ®Google Scholar
• Nyberg P, Heikkila P, Sorsa T, et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem. 2003;278:22404–22411.
   PubMed Web of Science ®Google Scholar